Contact UsHome

Starting a POC Group >

POCC of the Year >

POC Vendors >

Publications >

POC Procedures >

POC Groups


3Rivers (Western PA)

Alabama

Arizona

Baltimore/Chesapeake Bay

Bay Area (CA) 

Bay State (MA) 

Capitol (DC)

Central Florida 

Connecticut 

Delmarva 

First Coast Florida

Georgia 

Heart of America 

KEYPOCC

Louisiana 

Midwest 

New Jersey 

New York City 

North Carolina

North Country (MN)

North Texas

Northwest (OR)

Ohio 

Ontario (CN) 

Puget Sound (WA) 

Rocky Mountain

San Diego 

South Carolina

Southern California 

Southwest Florida 

Southwest 

Tennessee 

Texas Gulf Coast

Tri-State (IL) 

Upstate NY 

Virginia


WEB LINKS


LabTestsOnline.org


NACB Guidelines


Journal of Point of Care Testing


POC Demographics Survey


 

POC Meeting, Webinars, and Events Calendar

2016 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

POCT NEWS


New Vendor Listing
PTS Website
POC Vendor Listing




2016 Meetings, Events and Webinars are now being scheduled.

Click on a month above to see what's happening, where it's happening and what the topics are. Have a POC meeting or event in the works? Send the date(s) and details here so we can post on the calendar.

Monitoring Point-of-Care Testing Compliance
Olga Camacho-Ryan, MBA, MT(ASCP), and Roger L. Bertholf, PhD, DABCC, Clinical Laboratory News, February 2016

Beginning in the 1980s, point-of-care testing (POCT) departed from conventional clinical laboratory medicine by decentralizing laboratory services. Deploying POCT devices created challenges for laboratory management, especially in ensuring the proper use of these devices. Today, point-of-care coordinators use a variety of processes to maintain control over multiple devices and monitor regulatory compliance of many operators at locations across healthcare enterprises.

Early POCT methods were mostly manual, with minimal or no quality control and limited data management capabilities. Modern POCT devices.... Read more >

Abbott to Acquire Alere

 

Abbott and Alere Inc. announced on Monday, February 1, a definitive agreement for Abbott to acquire Alere, significantly advancing Abbott's global diagnostics presence and leadership. Once the transaction is completed, Abbott will become the leading diagnostics provider of point of care testing.  Abbott Release  Joint Release

Management of Diabetes: The Future is Now
MLO | February 2016 | By: Ross Molinaro and Carole Dauscher

Diabetes is a worldwide epidemic. Its prevalence continues to rise globally at an average rate of 8.7 percent, and it currently affects 382 million of the world’s population. Significant increases in populations diagnosed with diabetes have been reported by many nations as their lifestyle and dietary norms evolve with globalization. National healthcare budgets bear the financial burden of treating diabetes and its complications, exceeding $548 billion dollars globally.

Through the power of diagnostic testing to help screen, diagnose, and monitor, a patient’s chronic condition can be kept in balance and not allowed to escalate to a critical state that lessens quality of life and may require hospitalization and more expensive intervention.

The impact of diabetes and how POC enhances management
Diabetes is defined as a chronic disease that occurs when the pancreas is no longer able to make insulin or when the body cannot make good use of the insulin it produces. Not being able to produce insulin or use it effectively leads to raised glucose levels in the blood (known as hyperglycemia). Over the long-term, high glucose levels are a threat to well-being, and are associated with damage to the body and failure of various organs and tissues. More >

Latest HbA1c Debate Examines Race

as Nonglycemic Factor
By Kevin B. O’Reilly, CAP Today

In 2010, the American Diabetes Association endorsed the use of hemoglobin A1c to diagnose type 2 diabetes, and fierce arguments over the wisdom of that move have ensued ever since. A 2013 debate at the American Association for Clinical Chemistry’s annual meeting featured a spirited dialogue on the merits of using HbA1c as a diagnostic marker, compared with the traditional—and still ADA recommended—alternatives, fasting plasma glucose and two-hour plasma glucose.

Now the discussion is zeroing in on a narrower controversy within the HbA1c dispute—the role of race and ethnicity. African-Americans regularly have higher HbA1c values than do whites, even when they have similar fasting plasma glucose levels. Hispanics, too, have exhibited a similar HbA1c/FPG disparity, though amid a smaller body of research and to a lesser degree than is found among blacks. The questions are what this widely observed trend means and what to do about it. More >

White Paper

How Point-of-Care Testing Improves

More Than Your Bottom Line
Hospitals need faster results, better decisions, and improved patient outcomes

Hospital decision makers, including C-suite executives, face new economic and clinical challenges every day. To help address these challenges in an environment where the Affordable Care Act (ACA) and Centers for Medicare and Medicaid Services (CMS) require new value-based measures, it’s imperative that testing procedures help reduce readmissions while increasing productivity.

The role of point-of-care testing in improving health care outcomes is an informative white paper that discusses and demonstrates how point-of-care testing devices can improve clinical benefits for patients, as well as operational, economic, and compliance benefits for hospitals and other health care institutions. It’s information you’ll want to know.

Download the free white paper here >

Guide to Urinalysis Instrumentation

It is arguably the oldest discipline in pathology, but that title likely would not be enough to generate sentimental feelings among those at the receiving end of a urinalysis test. Yet urinalysis is a Cinderella of sorts: morphing from visual observation, to taste testing, to manual dipstick tests, to sleek, state-of-the-art instrumentation that can measure numerous substances.

 

Showing off their features are 10 urinalysis instruments that, collectively, represent CAP TODAY’s first urinalysis systems product guide. The guide focuses on fully automated and semiautomated urine chemistry and microscopy/sediment instrumentation.  More on this article >  |  More on the Guide >

IQCP for POCT
Q&A helps demystify process of starting an Individualized

Quality Control Plan
By Valerie Neff Newitt, December 28, 2015, Advance for Administrators of the lab, Vol. 25

Quality control continues to be problematic for point-of-care tests (POCT). According to literature, 75 percent of arterial blood gas (ABG) testing errors can be attributed to pre-analytical errors.1 And CMS has noted that 19% of POCT operators were not trained for the testing they were performing. Such inconsistencies spell trouble for lab managers responsible for overseeing POCT quality. More >

Is Your POCT Program Inspection-Ready?
By Connie Mardis and Daniel Gundler, MLO, December 2015

For point-of-care (POC) devices operating under the central laboratory license, the single biggest challenge for the adoption of POC testing is maintaining control, regulatory compliance, and training records for thousands of operators performing testing in anywhere from 30 to 50 locations within the hospital. This article will review the new Individual Quality Control Plan (IQCP) option slated to take effect on January 1, 2016, and present strategies and tools available to ease the burden of regulatory compliance and inspection preparedness.

CLIA certificates and POC complexity

In the United States all clinical testing, no matter where it is performed, is regulated by the Clinical Laboratory Improvement Amendments of 1988 (CLIA). In the CLIA-exempt states of Washington and New York, laboratories receive a state license, and must, at a minimum, comply with CLIA rules, in addition to their individual state’s regulations. More >

Assessing New Molecular Influenza Tests
Clinical Lab Products, November 2015, By Sheldon Campbell, MD, PhD, FCAP, and Norman Moore, PhD

Following best practices can help labs maximize the utility and cost-effectiveness of flu testing.

Screening for influenza infection may be important for improving patient outcomes and reducing the public health impact of this potentially deadly illness. Yet, despite the availability of dozens of influenza testing devices, most such tests do not realize the full potential of diagnosis because they do not provide highly accurate results quickly enough for healthcare providers to make informed treatment decisions while the patient is still under their care.

The combination of suboptimal diagnosis, the highly transmissible nature of the virus, and the wide overlap of symptoms with more urgent conditions like pneumonia, has led to widespread empirical treatment, and sometimes overtreatment, of patients who present with influenza-like illness. More >

The "Tricorder" of Patient Care
From glucometers to genetics and the future of testing
By Silas Gossman, October 26, 2015, Advance for Administrators of the Laboratory

The healthcare paradigm is moving rapidly toward point-of-care testing (POCT) in several areas. With this dramatic move, however, there are several issues to take under consideration. The benefits entail such things as increased timeliness of results and convenience for patients. Among the potential issues, however, are the possible costs of these tests, the reliability of the machines and the standards of quality and regulations hospitals must work to meet with the added equipment.

 

This article follows the thoughts of several experienced practitioners in the field of POCT, including Mark Crowther, MD, at McMaster University, Kim Gregory MT (ASCP), NCA, CLS, Associate Director, POCT at Massachusetts General Hospital and Lara Moody, MLT (ASCP), coordinator of POCT at Dartmouth-Hitchcock Medical Center in Lebanon, NH.

Q&A with Kimberly Gregory:
ADVANCE: In what fields do you see POCT having the most untapped potential applications? More >

Note: Parts 1 and 3 of this article can also be accessed on the Advance for Administrators of the Laboratory website.

Point-of-Care Testing Continues Growth
Greater Speed and Accuracy Mark POC Trends
By Gary Tufel, Clinical Lab Products

Sometimes referred to under the heading of “near-patient” or “bedside” testing, point-of-care (POC) diagnostics encompass a variety of test platforms that sometimes appear to have very little in common with one another. What they do have in common is their focused ability to provide simple, rapid testing, often of blood or urine samples, and to be administered physically close to the location of the test subject. Some are administered in medical settings, and some at home; some are simple kits meant for use in settings where electricity and other resources might not be readily available, and some are sophisticated instruments with broad information technology capabilities. More >

PRIDE Statement on the Need for a Moratorium on the CMS Plan to Cite Hospitals...

...for Performing POC Capillary Glucose Monitoring on the Critically Ill
David C. Klonoff, Boris Draznin, Andjela Drincic, Kathleen Dungan, Roma Gianchandani, Silvio E. Inzucchi, James H. Nichols, Mark J. Rice, and Jane Jeffrie Seley, J Clin Endocrinol Metab

A writing committee of the Planning Research in Inpatient Diabetes (PRIDE) group has
written this consensus article on behalf of the group in response to a specific request for input from the Centers for Medicare and Medicaid Services (CMS). The purpose of this article is to respond to the March 13, 2015 statement from that agency regarding plans to enforce prohibition of the off-label use of point of care (POC) capillary blood glucose monitor (BGM) testing in most critically ill patients. The article discusses:

  1. How POC BGM testing is currently regulated;

  2. How POC BGM testing is currently used in the United States; and

  3. How POC BGM testing can be safely and effectively regulated in the future through cooperation between the clinician, laboratory, regulatory, industry, and patient communities.

For more on this article, visit the The Journal of Clinical Endocrinology & Metabolism

(JCEM). Please note that JCEM requires a subscription to this article's content.

 

Click here for more stories in our Article Archives...

Resources

POCT on CAP



Quality Control

EP Evaluator®


Last updated: 02/03/2016 Questions or corrections: editor@pointofcare.net. © 2015  BACK TO TOP